Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

IFNG overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

IFNG overexpression	Pancreatic Cancer	IFNG overexpression	Pancreatic Cancer	anlotinib + penpulimab Sensitive: C3 – Early Trials ESMO Asia 2023 - 1 week (New C3) anlotinib + penpulimab Sensitive : C3 ESMO Asia 2023 - 1wk	anlotinib + penpulimab Sensitive: C3 – Early Trials ESMO Asia 2023 - 1 week anlotinib + penpulimab Sensitive : C3 ESMO Asia 2023 - 1 week - (New C3)
IFNG overexpression	Melanoma	IFNG overexpression	Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
IFNG overexpression	Non Small Cell Lung Cancer	IFNG overexpression	Non Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
IFNG overexpression	Squamous Cell Carcinoma of Head and Neck	IFNG overexpression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
IFNG overexpression	Biliary Tract Cancer	IFNG overexpression	Biliary Tract Cancer	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3
IFNG overexpression	Esophageal Squamous Cell Carcinoma	IFNG overexpression	Esophageal Squamous Cell Carcinoma	toripalimab Sensitive: C3 – Early Trials toripalimab Sensitive : C3	toripalimab Sensitive: C3 – Early Trials toripalimab Sensitive : C3